Archive for January 2024
Accurate Sepsis Identification Using Septicyte Rapid And Other Biomarkers Of Systemic Inflammation
Accurate Identification of Sepsis using SeptiCyte® RAPID and Comparison with other Biomarkers Presented at Society of Critical Care Medicine Critical Care Congress 2024
This press release was first published at PR Newswire SEATTLE and BRISBANE, Australia, Jan. 22, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during…
Read MoreImmunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®
EDTA blood collection tubes are used routinely in clinical settings for hematology procedures around the world SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug…
Read More“Immunexpress Nabs 510(k) Clearance for EDTA Blood-Compatible Cartridges”
Via 360Dx, ” Jan 04, 2024 | staff reporter NEW YORK – Immunexpress announced Thursday that it has secured US Food and Drug Administration 510(k) clearance for ethylenediaminetetraacetic acid (EDTA) blood-compatible cartridges for use with the firm’s SeptiCyte Rapid test to differentiate sepsis from infection-negative systemic inflammation. Read the rest here: 360Dx
Read MoreSeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA)
The Cost of Sepsis in Australia report (2021) estimated that there are >90,000 sepsis cases in Australia each year and estimated direct and indirect costs of $700 million and $4 billion respectively SEATTLE and BRISBANE, Australia, Jan. 17, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis…
Read More